jetcityimage/iStock Editorial via Getty Images
- Eli Lilly’s (NYSE:LLY) weight loss therapy tirzepatide will be available in Britain starting this week as the U.K. drug store chains Superdrug and Simple Online Pharmacy announced their plans to roll out the popular GLP-1 agonist used for both obesity and diabetes.
- The rollout comes weeks after the U.K. drug regulator Medicines and Healthcare products Regulatory Agency (MHRA) authorized LLY’s “KwikPen,” an injection pen designed for the convenient delivery of four weekly subcutaneous shots in one device.
- At the time, the Indiana-based drugmaker said Britain would be the first major market where tirzepatide would be available in KwikPen format, and its supplies would begin within weeks.
- Superdrug is launching tirzepatide at £215 ($270) for 2.5 mg and 5 mg starter doses under its private service on Thursday.
- The drug branded as Mounjaro for diabetes and Zepbound for obesity in the U.S. has already been made available at Simple Online Pharmacy for £189 ($237) for starter doses. In December, Lilly (LLY) launched Zepbound at a list price of approximately $1,060 for all six dose levels.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
